TY - JOUR
T1 - Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after infection
AU - Canto e Castro, Luísa
AU - Gomes, Andreia
AU - Serrano, Marta
AU - Pereira, Ana Helena Guia
AU - Ribeiro, Rita
AU - Napoleão, Patrícia
AU - Domingues, Inês
AU - Silva, Cláudia
AU - Fanczal, Júlia
AU - Afonso, Ângela
AU - Lopes, Andreia
AU - Toader, Ionela
AU - de Sousa, Maria José Rego
AU - de Sousa, José Germano Rego
AU - de Sousa, Germano
AU - Mota, Maria M.
AU - Silva-Santos, Bruno
AU - Veldhoen, Marc
AU - Ribeiro, Ruy M.
N1 - Publisher Copyright:
© 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH
PY - 2022/1
Y1 - 2022/1
N2 - During the COVID-19 pandemic, Portugal has experienced three distinct SARS-CoV-2 infection waves. We previously documented the prevalence of SARS-CoV-2 immunity, measured by specific antibodies, in September 2020, 6 months after the initial moderate wave. Here, we show the seroprevalence changes 6 months later, up to the second week of March 2021, shortly following the third wave, which was one of the most severe in the world, and 2 months following the start of the vaccination campaign. A longitudinal epidemiological study was conducted, with a stratified quota sample of the Portuguese population. Serological testing was performed, including ELISA determination of antibody class and titers. The proportion of seropositives, which was 2.2% in September 2020, rose sharply to 17.3% (95% CI: 15.8–18.8%) in March 2021. Importantly, circulating IgG and IgA antibody levels were very stable 6 months after the initial determination and up to a year after initial infection, indicating long-lasting infection immunity against SARS-CoV-2. Moreover, vaccinated people had higher IgG levels from 3 weeks post-vaccination when compared with previously infected people at the same time post-infection.
AB - During the COVID-19 pandemic, Portugal has experienced three distinct SARS-CoV-2 infection waves. We previously documented the prevalence of SARS-CoV-2 immunity, measured by specific antibodies, in September 2020, 6 months after the initial moderate wave. Here, we show the seroprevalence changes 6 months later, up to the second week of March 2021, shortly following the third wave, which was one of the most severe in the world, and 2 months following the start of the vaccination campaign. A longitudinal epidemiological study was conducted, with a stratified quota sample of the Portuguese population. Serological testing was performed, including ELISA determination of antibody class and titers. The proportion of seropositives, which was 2.2% in September 2020, rose sharply to 17.3% (95% CI: 15.8–18.8%) in March 2021. Importantly, circulating IgG and IgA antibody levels were very stable 6 months after the initial determination and up to a year after initial infection, indicating long-lasting infection immunity against SARS-CoV-2. Moreover, vaccinated people had higher IgG levels from 3 weeks post-vaccination when compared with previously infected people at the same time post-infection.
UR - http://www.scopus.com/inward/record.url?scp=85118901134&partnerID=8YFLogxK
U2 - 10.1002/eji.202149619
DO - 10.1002/eji.202149619
M3 - Article
C2 - 34695227
AN - SCOPUS:85118901134
SN - 0014-2980
VL - 52
SP - 149
EP - 160
JO - European Journal of Immunology
JF - European Journal of Immunology
IS - 1
ER -
